Cocrystal Pharma获得FDA研究性新药批准,开展口服广谱蛋白酶抑制剂CDI-988挑战性研究,该药物有望成为首个诺如病毒防治抗病毒药物
Cocrystal Pharma获得FDA研究性新药批准,开展口服广谱蛋白酶抑制剂CDI-988挑战性研究,该药物有望成为首个诺如病毒防治抗病毒药物
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.